CDK4 and head and neck squamous cell carcinoma: Furthermore, a phase 2 trial showed that the combination of a CDK4/6 inhibitor and cetuximab exhibited substantial antitumor activity in HNSCC, even in cetuximab-resistant patients, strongly suggesting that inhibition of CDK4/6 is a potential targeted therapeutic strategy in HNSCC40.